Arcturus' topical dexchlorpheniramine enters Phase Ib/II trials as anti-itch treatment.

This article was originally published in The Tan Sheet

06 Feb 1995
News

The Tan Sheet

Executive Summary

ARCTURUS BEGINS TOPICAL DEXCHLORPHENIRAMINE PHASE Ib/II STUDY as an anti-itch treatment for contact and atopic dermatitis, the dermatological R&D company announced Jan. 31. Arcturus Pharmaceutical said it expects the trial, which is a dose-escalating study in patients with atopic dermatitis, to be completed by the second half of 1995. The company hopes to begin Phase III efficacy trials by the end of the year.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
Consumer
Subjects
OTC Drugs

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Consumer OTC Drugs

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS083704

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS083704

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Arcturus' topical dexchlorpheniramine enters Phase Ib/II trials as anti-itch treatment.

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert